Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 8962763, 9 pages
http://dx.doi.org/10.1155/2016/8962763
Clinical Study

Influence of Insulin Resistance and TNF-α on the Inflammatory Process, Oxidative Stress, and Disease Activity in Patients with Rheumatoid Arthritis

1Department of Rheumatology, University of Londrina (UEL), Londrina, PR, Brazil
2Department of Clinical Analysis, University North of Paraná (UNOPAR), Londrina, PR, Brazil
3Department of Clinical Pathology, University of Londrina, Robert Koch Avenue No. 60 Bairro Cervejaria, Londrina 86038-440, PR, Brazil
4Department of Internal Medicine, University of Londrina, Londrina, PR, Brazil

Received 8 December 2015; Accepted 19 April 2016

Academic Editor: Victor M. Victor

Copyright © 2016 Neide Tomimura Costa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. D. del Rincón, K. Williams, M. P. Stern, G. L. Freeman, and A. Escalante, “High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors,” Arthritis and Rheumatism, vol. 44, no. 12, pp. 2737–2745, 2001. View at Google Scholar · View at Scopus
  2. S. E. Gabriel, “Cardiovascular morbidity and mortality in rheumatoid arthritis,” The American Journal of Medicine, vol. 121, no. 10, pp. S9–S14, 2008. View at Publisher · View at Google Scholar
  3. S. Haque, H. Mirjafari, and I. N. Bruce, “Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus,” Current Opinion in Lipidology, vol. 19, no. 4, pp. 338–343, 2008. View at Publisher · View at Google Scholar
  4. C. De Luca and J. M. Olefsky, “Inflammation and insulin resistance,” FEBS Letters, vol. 582, no. 1, pp. 97–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. El-Barbary, E. M. Kassem, M. A. S. El-Sergany, S. A.-M. Essa, and M. A. Eltomey, “Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide,” The Journal of Rheumatology, vol. 38, no. 5, pp. 828–834, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Saxne, M. A. Palladino Jr., D. Heinegard, N. Talal, and F. A. Wollheim, “Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum,” Arthritis and Rheumatism, vol. 31, no. 8, pp. 1041–1045, 1988. View at Publisher · View at Google Scholar · View at Scopus
  7. I. B. McInnes and G. Schett, “The pathogenesis of rheumatoid arthritis,” The New England Journal of Medicine, vol. 365, no. 23, pp. 2205–2219, 2011. View at Publisher · View at Google Scholar
  8. C. P. Chung, A. Oeser, J. F. Solus et al., “Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms,” Arthritis and Rheumatism, vol. 58, no. 7, pp. 2105–2112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. L. L. Prevoo, M. A. van't Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis & Rheumatism, vol. 38, no. 1, pp. 44–48, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Vasanthi, G. Nalini, and G. Rajasekhar, “Status of oxidative stress in rheumatoid arthritis,” International Journal of Rheumatic Diseases, vol. 12, no. 1, pp. 29–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. L. I. Filippin, R. Vercelino, N. P. Marroni, and R. M. Xavier, “Redox signalling and the inflammatory response in rheumatoid arthritis,” Clinical and Experimental Immunology, vol. 152, no. 3, pp. 415–422, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. C. A. Hitchon and H. S. El-Gabalawy, “Oxidation in rheumatoid arthritis,” Arthritis Research and Therapy, vol. 6, no. 6, pp. 265–278, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Taysi, F. Polat, M. Gul, R. Sari, and E. Bakan, “Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis,” Rheumatology International, vol. 21, no. 5, pp. 200–204, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Z. Hassan, T. A. Gheita, S. A. Kenawy, A. T. Fahim, I. M. El-Sorougy, and M. S. Abdou, “Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity,” International Journal of Rheumatic Diseases, vol. 14, no. 4, pp. 325–331, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Kageyama, M. Takahashi, T. Nagafusa, E. Torikai, and A. Nagano, “Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis,” Rheumatology International, vol. 28, no. 3, pp. 245–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Shahmohamadnejad, A. Vaisi-Raygani, Y. Shakiba et al., “Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: correlation with systemic inflammatory markers and oxidative stress, preliminary report,” Clinical Biochemistry, vol. 48, no. 1-2, pp. 63–69, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. B. Lozovoy, A. N. C. Simão, M. S. N. Hohmann et al., “Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome,” Lupus, vol. 20, no. 13, pp. 1356–1364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. B. Lozovoy, A. N. C. Simão, S. R. Oliveira et al., “Relationship between iron metabolism, oxidative stress, and insulin resistance in patients with systemic lupus erythematosus,” Scandinavian Journal of Rheumatology, vol. 42, no. 4, pp. 303–310, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. R. Oliveira, A. N. Colado Simão, A. P. Kallaur et al., “Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress,” Nutrition, vol. 30, no. 3, pp. 268–273, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. H. K. Morimoto, A. N. C. Simão, E. R. D. D. Almeida et al., “Role of metabolic syndrome and antiretroviral therapy in adiponectin levels and oxidative stress in HIV-1 infected patients,” Nutrition, vol. 30, no. 11-12, pp. 1324–1330, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. P. H. Dessein and B. I. Joffe, “Insulin resistance and impaired beta cell function in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 9, pp. 2765–2775, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. G. La Montagna, F. Cacciapuoti, R. Buono et al., “Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis,” Diabetes and Vascular Disease Research, vol. 4, no. 2, pp. 130–135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Arcaro, “Insulin causes endothelial dysfunction in humans: sites and mechanisms,” Circulation, vol. 105, no. 5, pp. 576–582, 2002. View at Publisher · View at Google Scholar
  24. Y. Kageyama, M. Takahashi, T. Ichikawa, E. Torikai, and A. Nagano, “Reduction of oxidative stress marker levels by anti-TNF-α antibody, infliximab, in patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 26, no. 1, pp. 73–80, 2008. View at Google Scholar · View at Scopus
  25. O. Altindag, M. Karakoc, A. Kocyigit, H. Celik, and N. Soran, “Increased DNA damage and oxidative stress in patients with rheumatoid arthritis,” Clinical Biochemistry, vol. 40, no. 3-4, pp. 167–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Nakajima, Y. Aoki, Y. Shibata et al., “Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 24, no. 6, pp. 926–930, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Aletaha, T. Neogi, and A. J. Silman, “2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 69, no. 10, pp. 1580–1588, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. M. Haffner, H. Miettinen, and M. P. Stern, “The homeostasis model in the San Antonio Heart Study,” Diabetes Care, vol. 20, no. 7, pp. 1087–1092, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Gonzalez Flecha, S. Llesuy, and A. Boveris, “Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver, and muscle,” Free Radical Biology and Medicine, vol. 10, no. 2, pp. 93–100, 1991. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Witko-Sarsat, M. Friedlander, T. N. Khoa et al., “Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure,” The Journal of Immunology, vol. 161, no. 5, pp. 2524–2532, 1998. View at Google Scholar · View at Scopus
  31. M. Repetto, C. Reides, M. L. Gomez Carretero, M. Costa, G. Griemberg, and S. Llesuy, “Oxidative stress in blood of HIV infected patients,” Clinica Chimica Acta, vol. 255, no. 2, pp. 107–117, 1996. View at Publisher · View at Google Scholar · View at Scopus
  32. G. S. Hotamisligil, “Molecular mechanisms of insulin resistance and the role of the adipocyte,” International Journal of Obesity, vol. 24, supplement 4, pp. S23–S27, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Popa, M. G. Netea, P. L. C. M. Van Riel, J. W. M. Van Der Meer, and A. F. H. Stalenhoef, “The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk,” Journal of Lipid Research, vol. 48, no. 4, pp. 751–752, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. H. Dessein, B. I. Joffe, A. E. Stanwix, B. F. Christian, and M. Veller, “Glucocorticoids and insulin sensitivity in rheumatoid arthritis,” The Journal of Rheumatology, vol. 31, no. 5, pp. 867–874, 2004. View at Google Scholar · View at Scopus
  35. K. L. G. Svenson, G. Lundqvist, L. Wide, and R. Hällgren, “Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment,” Metabolism, vol. 36, no. 10, pp. 944–948, 1987. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Penesová, Z. Rádiková, M. Vlček et al., “Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors,” Physiological Research, vol. 62, no. 1, pp. 75–83, 2013. View at Google Scholar · View at Scopus
  37. J. M. Sabio, J. A. Vargas-Hitos, N. Navarrete, C. Hidalgo-Tenorio, and J. Jiménez-Alonso, “Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 28, no. 4, pp. 483–489, 2010. View at Google Scholar · View at Scopus
  38. L.-S. Tam, B. Tomlinson, T. T. Chu, T. K. Li, and E. K. Li, “Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis,” Clinical Rheumatology, vol. 26, no. 9, pp. 1495–1498, 2007. View at Publisher · View at Google Scholar
  39. D. E. Moller, “Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes,” Trends in Endocrinology and Metabolism, vol. 11, no. 6, pp. 212–217, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Hayakawa, Y. Nagai, M. Taniguchi et al., “Tumor necrosis factor-β gene NcoI polymorphism decreases insulin resistance in Japanese men,” Metabolism: Clinical and Experimental, vol. 49, no. 11, pp. 1506–1509, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. J. A. Singh, D. E. Furst, A. Bharat et al., “2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis,” Arthritis Care & Research, vol. 64, no. 5, pp. 625–639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Lo, L. E. Bernstein, B. Canavan et al., “Effects of TNF-α neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome,” American Journal of Physiology—Endocrinology and Metabolism, vol. 293, no. 1, pp. E102–E109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. K. J. Grattendick, J. M. Nakashima, L. Feng, S. N. Giri, and S. B. Margolin, “Effects of three anti-TNF-α drugs: etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro,” International Immunopharmacology, vol. 8, no. 5, pp. 679–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Bhatia and R. E. Kast, “Tumor Necrosis Factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease,” Journal of Rheumatology, vol. 34, no. 2, pp. 447–449, 2007. View at Google Scholar · View at Scopus
  45. M. Biniecka, A. Kennedy, C. T. Ng et al., “Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis,” Arthritis Research and Therapy, vol. 13, no. 4, article R121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. A. A. den Broeder, G. J. A. Wanten, W. J. G. Oyen, T. Naber, P. L. C. M. Van Riel, and P. Barrera, “Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-α monoclonal antibody in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 30, no. 2, pp. 232–237, 2003. View at Google Scholar · View at Scopus
  47. I. Stagakis, G. Bertsias, S. Karvounaris et al., “Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance,” Arthritis Research and Therapy, vol. 14, no. 3, article R141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Stavropoulos-Kalinoglou, G. S. Metsios, V. F. Panoulas, P. Nightingale, Y. Koutedakis, and G. D. Kitas, “Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis,” Arthritis Research and Therapy, vol. 14, no. 4, article R160, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. P. Biemond, A. J. G. Swaak, and J. F. Koster, “Protective factors against oxygen free radicals and hydrogen peroxide in rheumatoid arthritis synovial fluid,” Arthritis and Rheumatism, vol. 27, no. 7, pp. 760–765, 1984. View at Publisher · View at Google Scholar · View at Scopus
  50. C.-H. Woo, T.-H. Kim, J.-A. Choi et al., “Inhibition of receptor internalization attenuates the TNFα-induced ROS generation in non-phagocytic cells,” Biochemical and Biophysical Research Communications, vol. 351, no. 4, pp. 972–978, 2006. View at Publisher · View at Google Scholar
  51. K. Schulze-Osthoff, P. H. Krammer, and W. Dröge, “Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death,” The EMBO Journal, vol. 13, no. 19, pp. 4587–4596, 1994. View at Google Scholar · View at Scopus
  52. K. Hirose, D. L. Longo, J. J. Oppenheim, and K. Matsushima, “Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation,” FASEB Journal, vol. 7, no. 2, pp. 361–368, 1993. View at Google Scholar · View at Scopus
  53. R. Miesel, M. P. Murphy, and H. Kröger, “Enhanced mitochondrial radical production in patients with rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma,” Free Radical Research, vol. 25, no. 2, pp. 161–169, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. E. Mur, A. Zabernigg, W. Hilbe, W. Eisterer, W. Halder, and J. Thaler, “Oxidative burst of neutrophils in patients with rheumatoid arthritis: influence of various cytokines and medication,” Clinical and Experimental Rheumatology, vol. 15, no. 3, pp. 233–237, 1997. View at Google Scholar · View at Scopus
  55. G. Bonizzi, J. Piette, M.-P. Merville, and V. Bours, “Cell type-specific role for reactive oxygen species in nuclear factor-kappaB activation by interleukin-1,” Biochemical Pharmacology, vol. 59, no. 1, pp. 7–11, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Coaccioli, A. Panaccione, R. Biondi et al., “Evaluation of oxidative stress in rheumatoid and psoriatic arthritis and psoriasis,” Clinica Terapeutica, vol. 160, no. 6, pp. 467–472, 2009. View at Google Scholar · View at Scopus